Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Luca Durelli, Mauro Zaffaroni, Pierangelo Barbero et al.|The Lancet|2002Cited by 552
Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple SclerosisMarco Rovaris, Massimo Filippi, Marco Bozzali et al.|Archives of Neurology|2002Cited by 223
Thyroid Function and Autoimmunity during Interferon β-1b Treatment: A Multicenter Prospective StudyLuca Durelli, Mauro Zaffaroni, Bruno Ferrero et al.|The Journal of Clinical Endocrinology & Metabolism|2001Cited by 47
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Simona Malucchi, Marco Capobianco et al.|Neurological Sciences|2013Cited by 37
Ethical Decision Making in Iot Data Driven Research: A Case Study of a Large-Scale PilotSofia Segkouli, Konstantinos Votis, Giuseppe Fico et al.|Healthcare|2022Cited by 6